← Leaderboards
Susanne Irmtraud Wells
Cincinnati Childrens Hosp Med Ctr
$12,656,530
Attributed
$14,626,204
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,626,204 · 9
By mechanism
R01$14,093,562 · 7
R21$437,250 · 1
U01$95,392 · 1
Top collaborators
- Susan E Waltz5 shared
- David F Smith4 shared
- Alessandro Dealarcon2 shared
- Kathryn Ann Wikenheiser-Brokamp1 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Ruhikanta Amom Meetei$2,117,069
- Lisa M. Privette Vinnedge$2,960,069
- Alessandro Dealarcon$947,343
- David F Smith$1,410,244
- Richard J Morreale$50,054
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsPhenotypeMolecularPathway InteractionsTumorSignal TransductionKeratinocyteHuman PapillomavirusLinkOncogenesReportingGrowthProductionProteinsGenesMapsCancer CellMalignant NeoplasmsIn VivoTherapeutic TargetPublishingCell TypeRegulationCancer Therapy
Grant awards (45)
HPV and host factors in juvenile onset recurrent respiratory papillomatosis$446,728
R01 · FY2025 · CA · contact PI
Cell-Cell Signaling Driving HPV-Induced Respiratory Disease and Vaccine Response$95,392
U01 · FY2025 · CA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$452,218
R01 · FY2024 · CA
HPV and host factors in juvenile onset recurrent respiratory papillomatosis$446,728
R01 · FY2024 · CA · contact PI
New activities of the human DEK oncogene$344,256
R01 · FY2024 · CA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$466,499
R01 · FY2023 · CA
New activities of the human DEK oncogene$355,127
R01 · FY2023 · CA · contact PI
Strengthening epidermal defenses for the prevention of HPV infection and replication$315,534
R01 · FY2023 · CA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$466,496
R01 · FY2022 · CA
FA pathway activities in the normal and transformed epidermis$356,438
R01 · FY2022 · CA · contact PI
New activities of the human DEK oncogene$355,127
R01 · FY2022 · CA · contact PI
Strengthening epidermal defenses for the prevention of HPV infection and replication$315,534
R01 · FY2022 · CA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$476,019
R01 · FY2021 · CA
Strengthening epidermal defenses for the prevention of HPV infection and replication$386,368
R01 · FY2021 · CA · contact PI
FA pathway activities in the normal and transformed epidermis$363,713
R01 · FY2021 · CA · contact PI
New activities of the human DEK oncogene$362,374
R01 · FY2021 · CA · contact PI
Defining genetic and metabolic requirements of aggressive breast cancer$506,269
R01 · FY2020 · CA
Strengthening epidermal defenses for the prevention of HPV infection and replication$386,370
R01 · FY2020 · CA · contact PI
New activities of the human DEK oncogene$375,871
R01 · FY2020 · CA · contact PI
FA pathway activities in the normal and transformed epidermis$363,713
R01 · FY2020 · CA · contact PI
Therapeutic target discovery in pediatric recurrent respiratory papillomatosis$198,750
R21 · FY2020 · AI · contact PI
FA pathway activities in the normal and transformed epidermis$352,801
R01 · FY2019 · CA · contact PI
Strengthening epidermal defenses for the prevention of HPV infection and replication$321,973
R01 · FY2019 · CA · contact PI
Therapeutic target discovery in pediatric recurrent respiratory papillomatosis$238,500
R21 · FY2019 · AI · contact PI
FA pathway activities in the normal and transformed epidermis$363,713
R01 · FY2018 · CA · contact PI
Role and Regulaton of the Human DEK Proto-Oncogene$265,615
R01 · FY2016 · CA · contact PI
Role and Regulaton of the Human DEK Proto-Oncogene$266,707
R01 · FY2015 · CA · contact PI
Role and Regulaton of the Human DEK Proto-Oncogene$258,705
R01 · FY2014 · CA · contact PI
Fanconi Anemia and HPV Transformation$275,896
R01 · FY2013 · CA · contact PI
Role and Regulaton of the Human DEK Proto-Oncogene$250,705
R01 · FY2013 · CA · contact PI
Fanconi Anemia and HPV Transformation$293,506
R01 · FY2012 · CA · contact PI
Role and Regulaton of the Human DEK Proto-Oncogene$266,707
R01 · FY2012 · CA · contact PI
Fanconi Anemia and HPV Transformation$293,506
R01 · FY2011 · CA · contact PI
Fanconi Anemia and HPV Transformation$301,759
R01 · FY2010 · CA · contact PI
Role and Regulation of the Human DEK Proto-Oncogene$258,530
R01 · FY2010 · CA · contact PI
Fanconi Anemia and HPV Transformation$299,947
R01 · FY2009 · CA · contact PI
Role and Regulation of the Human DEK Proto-Oncogene$258,530
R01 · FY2009 · CA · contact PI
Role and Regulation of the Human DEK Proto-Oncogene$219,317
R01 · FY2009 · CA · contact PI
Role and Regulation of the Human DEK Proto-Oncogene$258,530
R01 · FY2008 · CA · contact PI
Role and Regulation of the Human DEK Proto-Oncogene$295,530
R01 · FY2007 · CA · contact PI
Papillomavirus Proteins Mediating Cancer and Senescence$286,090
R01 · FY2007 · CA · contact PI
Papillomavirus Proteins Mediating Cancer and Senescence$294,634
R01 · FY2006 · CA · contact PI
Role and Regulation of the Human DEK Probe-Oncogene$266,029
R01 · FY2006 · CA · contact PI
Papillomavirus Proteins Mediating Cancer and Senescence$301,725
R01 · FY2005 · CA
Papillomavirus Proteins Mediating Cancer and Senescence$301,725
R01 · FY2004 · CA